| P2093 | author name string | Haura EB | |
| P2860 | cites work | Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience | Q30810434 |
| | Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors | Q31960434 |
| | Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer | Q33329807 |
| | Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project | Q33330488 |
| | Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer | Q33330493 |
| | Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial | Q33330612 |
| | Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer | Q33331108 |
| | Oncolytic viruses | Q33888224 |
| | Cancer statistics, 2000. | Q33895772 |
| | Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues | Q34090957 |
| | Second-line chemotherapy for non-small-cell lung cancer | Q34107813 |
| | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 |
| | Chemotherapy of lung cancer | Q35234264 |
| | Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones | Q35858587 |
| | Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection | Q39425663 |
| | Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer | Q39461951 |
| | Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer | Q40626892 |
| | Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells | Q40866190 |
| | Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. | Q41524948 |
| | A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. | Q45162489 |
| | Gene replacement strategies for treating non-small cell lung cancer | Q45871835 |
| | Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study | Q50117137 |
| | Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. | Q53511212 |
| | Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. | Q53517685 |
| | Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. | Q53518274 |
| | Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 |
| | Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. | Q53531493 |
| | Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. | Q54048009 |
| P433 | issue | 4 | |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 326-336 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Cancer Control | Q15724614 |
| P1476 | title | Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies | |
| P478 | volume | 8 | |